CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
TAK-058 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02389881
NCT02389881Phase 1Completed
CompareCT.gov

A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058

Takeda·interventional·Posted Mar 17, 2015·Updated Feb 23, 2017

In Brief

A Phase 1 clinical trial evaluating TAK-058 and TAK-058 Placebo for Healthy Volunteers. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of TAK-058 in healthy non-elderly and elderly participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 17, 2015
Enrollment StartFeb 1, 2015
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.3 years ago

Interventions

TAK-058drug

TAK-058 Solution

TAK-058 Placebodrug

TAK-058 placebo-matching solution